281 related articles for article (PubMed ID: 21377448)
21. Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation.
Fernández-Nogueira P; Mancino M; Fuster G; López-Plana A; Jauregui P; Almendro V; Enreig E; Menéndez S; Rojo F; Noguera-Castells A; Bill A; Gaither LA; Serrano L; Recalde-Percaz L; Moragas N; Alonso R; Ametller E; Rovira A; Lluch A; Albanell J; Gascon P; Bragado P
Clin Cancer Res; 2020 Mar; 26(6):1432-1448. PubMed ID: 31699826
[TBL] [Abstract][Full Text] [Related]
22. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy.
Li X; Lewis MT; Huang J; Gutierrez C; Osborne CK; Wu MF; Hilsenbeck SG; Pavlick A; Zhang X; Chamness GC; Wong H; Rosen J; Chang JC
J Natl Cancer Inst; 2008 May; 100(9):672-9. PubMed ID: 18445819
[TBL] [Abstract][Full Text] [Related]
23. Lapatinib and HER2 status: results of a meta-analysis of randomized phase III trials in metastatic breast cancer.
Amir E; Ocaña A; Seruga B; Freedman O; Clemons M
Cancer Treat Rev; 2010 Aug; 36(5):410-5. PubMed ID: 20100635
[TBL] [Abstract][Full Text] [Related]
24. Exploring mechanisms of acquired resistance to HER2 (human epidermal growth factor receptor 2)-targeted therapies in breast cancer.
Creedon H; Byron A; Main J; Hayward L; Klinowska T; Brunton VG
Biochem Soc Trans; 2014 Aug; 42(4):822-30. PubMed ID: 25109964
[TBL] [Abstract][Full Text] [Related]
25. Mechanisms of lapatinib resistance in HER2-driven breast cancer.
D'Amato V; Raimondo L; Formisano L; Giuliano M; De Placido S; Rosa R; Bianco R
Cancer Treat Rev; 2015 Dec; 41(10):877-83. PubMed ID: 26276735
[TBL] [Abstract][Full Text] [Related]
26. RON confers lapatinib resistance in HER2-positive breast cancer cells.
Wang Q; Quan H; Zhao J; Xie C; Wang L; Lou L
Cancer Lett; 2013 Oct; 340(1):43-50. PubMed ID: 23811285
[TBL] [Abstract][Full Text] [Related]
27. Lapatinib: new directions in HER2 directed therapy for early stage breast cancer.
Jo Chien A; Rugo HS
Cancer Treat Res; 2009; 151():197-215. PubMed ID: 19593514
[No Abstract] [Full Text] [Related]
28. Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy.
Giuliano M; Hu H; Wang YC; Fu X; Nardone A; Herrera S; Mao S; Contreras A; Gutierrez C; Wang T; Hilsenbeck SG; De Angelis C; Wang NJ; Heiser LM; Gray JW; Lopez-Tarruella S; Pavlick AC; Trivedi MV; Chamness GC; Chang JC; Osborne CK; Rimawi MF; Schiff R
Clin Cancer Res; 2015 Sep; 21(17):3995-4003. PubMed ID: 26015514
[TBL] [Abstract][Full Text] [Related]
29. HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma.
Liu YJ; Shen D; Yin X; Gavine P; Zhang T; Su X; Zhan P; Xu Y; Lv J; Qian J; Liu C; Sun Y; Qian Z; Zhang J; Gu Y; Ni X
Br J Cancer; 2014 Mar; 110(5):1169-78. PubMed ID: 24518603
[TBL] [Abstract][Full Text] [Related]
30. Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb) in human breast carcinoma cells.
Vazquez-Martin A; Oliveras-Ferraros C; Colomer R; Brunet J; Menendez JA
Ann Oncol; 2008 Jun; 19(6):1097-109. PubMed ID: 18283037
[TBL] [Abstract][Full Text] [Related]
31. Lapatinib for breast cancer: a review of the current literature.
MacFarlane RJ; Gelmon KA
Expert Opin Drug Saf; 2011 Jan; 10(1):109-21. PubMed ID: 21091041
[TBL] [Abstract][Full Text] [Related]
32. Testican-1-mediated epithelial-mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer.
Kim HP; Han SW; Song SH; Jeong EG; Lee MY; Hwang D; Im SA; Bang YJ; Kim TY
Oncogene; 2014 Jun; 33(25):3334-41. PubMed ID: 23873022
[TBL] [Abstract][Full Text] [Related]
33. PRKACA mediates resistance to HER2-targeted therapy in breast cancer cells and restores anti-apoptotic signaling.
Moody SE; Schinzel AC; Singh S; Izzo F; Strickland MR; Luo L; Thomas SR; Boehm JS; Kim SY; Wang ZC; Hahn WC
Oncogene; 2015 Apr; 34(16):2061-71. PubMed ID: 24909179
[TBL] [Abstract][Full Text] [Related]
34. Mislocalization of p27 to the cytoplasm of breast cancer cells confers resistance to anti-HER2 targeted therapy.
Zhao H; Faltermeier CM; Mendelsohn L; Porter PL; Clurman BE; Roberts JM
Oncotarget; 2014 Dec; 5(24):12704-14. PubMed ID: 25587029
[TBL] [Abstract][Full Text] [Related]
35. Improving treatment of HER2-positive cancers: opportunities and challenges.
Stern HM
Sci Transl Med; 2012 Mar; 4(127):127rv2. PubMed ID: 22461643
[TBL] [Abstract][Full Text] [Related]
36. Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways.
Wang H; Lu J; Tang J; Chen S; He K; Jiang X; Jiang W; Teng L
BMC Cancer; 2017 Mar; 17(1):191. PubMed ID: 28292264
[TBL] [Abstract][Full Text] [Related]
37. HER2/neu may not be an interesting target in biliary cancers: results of an early phase II study with lapatinib.
Peck J; Wei L; Zalupski M; O'Neil B; Villalona Calero M; Bekaii-Saab T
Oncology; 2012; 82(3):175-9. PubMed ID: 22433475
[TBL] [Abstract][Full Text] [Related]
38. Neuromedin U: a candidate biomarker and therapeutic target to predict and overcome resistance to HER-tyrosine kinase inhibitors.
Rani S; Corcoran C; Shiels L; Germano S; Breslin S; Madden S; McDermott MS; Browne BC; O'Donovan N; Crown J; Gogarty M; Byrne AT; O'Driscoll L
Cancer Res; 2014 Jul; 74(14):3821-33. PubMed ID: 24876102
[TBL] [Abstract][Full Text] [Related]
39. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547.
Xie L; Su X; Zhang L; Yin X; Tang L; Zhang X; Xu Y; Gao Z; Liu K; Zhou M; Gao B; Shen D; Zhang L; Ji J; Gavine PR; Zhang J; Kilgour E; Zhang X; Ji Q
Clin Cancer Res; 2013 May; 19(9):2572-83. PubMed ID: 23493349
[TBL] [Abstract][Full Text] [Related]
40. Combined effects of lapatinib and bortezomib in human epidermal receptor 2 (HER2)-overexpressing breast cancer cells and activity of bortezomib against lapatinib-resistant breast cancer cells.
Ma C; Niu X; Luo J; Shao Z; Shen K
Cancer Sci; 2010 Oct; 101(10):2220-6. PubMed ID: 20701607
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
